BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

NCT03914742 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

67

Enrollment

OTHER

Sponsor class

Conditions

IDH1 Mutation
IDH2 Mutation
Recurrent Glioblastoma
Recurrent WHO Grade II Glioma
Recurrent WHO Grade III Glioma

Interventions

DRUG: PARP Inhibitor BGB-290
DRUG: Temozolomide
PROCEDURE: Therapeutic Conventional Surgery

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]